Here's Why Disease-Causing Bacteria Sent To International Space Station
The groundbreaking experiment includes E. coli, Salmonella bongori, and Salmonella typhimurium to study how microgravity affects bacterial growth and gene expression.
Scientists will study how space conditions impact bacterial behaviour, including antibiotic resistance and virulence, to better protect astronauts' health on long-duration missions.
"We know that space conditions affect bacterial behaviour, including how they grow, express genes, and acquire traits like antibiotic resistance or virulence," Prof Ohad Gal-Mor, Head of the Infectious Diseases Research Laboratory at Sheba Medical Center, said in a statement.
"This experiment will allow us, for the first time, to systematically and molecularly map how the genetic expression profile of several pathogenic bacteria changes in space."
The fact that bacteria behave differently in space is well-documented. They often grow faster and display altered characteristics. The bacteria might harm astronauts, especially during long-duration missions, as they are more prone to infections, because of a combination of microgravity, radiation, stress and changes in the human microbiome.
Hence, microbiology and immunology become vital components of modern and future space medicine.
Professor Gal-Mor said that the fresh insights will help our understanding of infectious disease risks in space travel, and also expand our knowledge of gene regulation and bacterial physiology in general.
The statement mentioned that the bacteria will be stabilised, frozen at -80 degrees C and returned to Earth after growth under microgravity. The molecular and transcriptional analysis and direct comparison to bacteria grown simultaneously in an identical lab setup on Earth.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
United News of India
39 minutes ago
- United News of India
Eli Lilly inaugurates Hyderabad site; plans to expand headcount to 1500 by next few years
Hyderabad, Aug 4 (UNI) US-based pharmaceutical giant Eli Lilly inaugurated its new Technology and innovation site in Hyderabad, today to accelerate Global digital innovation. Located in Gachibowli, the 220,000 square feet Hyderabad site will support innovation and strengthen digital capabilities across Lilly's global operations, a top official of the company said on the occasion.. The company has already onboarded 100 professionals at the facility and plans to expand the headcount to 1,500 over the next few years. By focusing on areas such as artificial intelligence (Al), automation, cloud computing, and software product engineering, the facility will contribute to solving some of the world's most pressing health challenges while also creating growth opportunities for local talent. Addressing after inaugurating US pharma major Eli Lilly's new technology and innovation facility in the presence of Miniter IT and Industries D Sridhar Babu and Diogo Rau, Executive Vice President and Chief Information and Digital officer, Eli Lilly and Company, here Chief Minister A Revanth Reddy said "We are not opening any ordinary centre or GCC, but a nerve-center of Eli Lilly, like the brain of the corporation will operate from here. It will manage, lead and accelerate Eli Lilly's global operations." The Hyderabad GCC will integrate Lilly's advanced technology capabilities across key functions, supporting accelerated innovation, enhanced efficiency, and improved health outcomes for patients globally, he said. The facility will support innovation and strengthen digital capabilities across Lilly's global operations. The new centre will create opportunities for local talent and advances Hyderabad's biotech ecosystem, he said. The Chief Minister described the launch as a clinching proof that in less than 20 months, with IT Minister D. Sridhar Babu's vision and hard work, the government made Hyderabad the Global GCC capital and hub. He said that the GCC growth in Hyderabad, in line with the Telangana Rising 2047 vision, will help in the state's roadmap to achieving a One Trillion Dollar economy. "We are proud that 1 in every 3 vaccines administered anywhere in the world is developed or manufactured in Hyderabad," he said that Hyderabad has become the preferred global destination for cutting-edge capability centers of the world's top pharmaceutical and biotechnology companies. The city is the Life Sciences capital of India, with presence of over 2,000 companies. The Chief Minister expressed commitment to providing a transparent, progressive and innovation-driven ecosystem, so that the Life Sciences industry can grow in scope and change the health sciences capabilities for the entire world. Sridar Babu said 'Hyderabad is rapidly emerging as a global epicentre for digital innovation, and Lilly's new site inauguration is a strong validation of that momentum. This investment reflects the transformative impact of technology on healthcare. Telangana remains committed to enabling future-focused partnerships that drive economic growth and advance digital health solutions for the world.' Diogo Rau said 'The inauguration of our Hyderabad site reflects our long-term commitment to India and our intent to strengthen our presence in the region.' 'This expansion brings together top talent in AI, data science, and engineering to build the digital foundation that will accelerate the discovery and delivery of innovative medicines. Hyderabad offers the perfect blend of deep technical expertise and a spirit of collaboration, making it a natural partner in our mission to make life better for people around the world', Rau added. UNI KNR RKM
Time of India
2 hours ago
- Time of India
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Why did Hims & Hers stock fall after earnings? Live Events Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Earnings beat estimates, but Wall Street stays cautious Is the GLP‑1 weight-loss business at risk? Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Hims keeps full-year guidance intact—thanks to international expansion Subscriber growth remains strong despite volatility What investors should watch going forward Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims still growing, but cracks are showing FAQs: (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever, raising questions about the future of itsDespite its rapid annual growth, Hims & Hers posted, missing the analyst estimate of. The real concern? Revenue dropped from, marking the first quarter-over-quarter decline since the company went stock currently trades at, regaining some ground after hitting an intraday low of. Despite opening at, it remains volatile, with an intraday high ofThe market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and were caught off guard, as the slowdown came amid soaring demand forlike semaglutide, a compound similar to the active ingredient in Wegovy and the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged:Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA.A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor:Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care company missed revenue estimates and saw its first-ever sequential drop in due to FDA scrutiny and legal issues around compounded semaglutide.
Time of India
2 hours ago
- Time of India
Clear labelling a must for paneer substitutes: FDA
Mumbai: The firmer variant of paneer increasingly used in institutional kitchens is not traditional milk-based paneer, but a substitute known as analogue paneer. In response to consumer complaints about misleading substitutions, the food and drugs administration (FDA) has mandated that establishments using this product must clearly display notices on premises, menus, or packaging, disclosing its composition. Although the use of cheese analogues in the food service sector has been legally permitted since 2021, FDA officials have raised concerns over their use as direct substitutes for paneer. These concerns stem from differences in their physicochemical properties and potential health implications. Hospitality sector representatives, including members of the AHAR (Association of Hotels and Restaurants) and HRAWI (Hotel and Restaurant Association of Western India), confirmed that many establishments have already implemented the required labelling protocols. Pradeep Shetty, owner of Maharaja Catering and spokesperson for HRAWI, said analogue paneer is cheaper to produce due to its use of alternative ingredients, but "menu disclosures are essential". Sudhakar Shetty, restaurateur and president of AHAR, said many major food chains are complying with the regulation, though wider public awareness is still lacking. Meanwhile, the Centre is reviewing a regulatory proposal to permit the addition of food-grade colouring agents to analogue paneer to enable easy visual differentiation from traditional paneer. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Jennifer Garner's sweet photo on sprawling family farm gets fans talking Watch More Undo You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai "Nutritionally, traditional paneer, produced by curdling milk, contains 18-20 grams of high-quality, complete protein per 100 grams, providing all nine essential amino acids necessary for muscle synthesis, tissue repair and metabolic functions," explained Rajesh Bothra, a Navi Mumbai-based nutritionist and gym trainer. "In contrast, cheese analogues typically contain only 7-10 grams of protein per 100 grams, often derived from plant sources that may lack a full amino acid profile unless specially fortified. " Nemaram Agarwal of Rajlaxmi Dairy in Powai said high consumer demand and limited supply have led some dairies to use powdered milk or even lower-quality analogue substitutes.
